Piper Sandler Downgrades Antares Pharma (ATRS) to Neutral
Tweet
Share
E-mailGet Alerts ATRS Hot Sheet
Price: $5.59 --0%
Rating Summary:
5 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 9
Rating Summary:
5 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 9
Join SI Premium – FREE
Piper Sandler analyst David Amsellem downgraded Antares Pharma (NASDAQ: ATRS) from Overweight to Neutral with a price target of $5.60 (from $6.00).
For an analyst ratings summary and ratings history on Antares Pharma click here. For more ratings news on Antares Pharma click here.
Shares of Antares Pharma closed at $5.58 yesterday.
You May Also Be Interested In
- BOK Financial (BOKF) PT Raised to $97 at DA Davidson
- Align Technology (ALGN) PT Raised to $375 at Piper Sandler
- First Busey (BUSE) PT Lowered to $24 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
